MX391168B - Derivados de acido graso y su uso. - Google Patents

Derivados de acido graso y su uso.

Info

Publication number
MX391168B
MX391168B MX2019015730A MX2019015730A MX391168B MX 391168 B MX391168 B MX 391168B MX 2019015730 A MX2019015730 A MX 2019015730A MX 2019015730 A MX2019015730 A MX 2019015730A MX 391168 B MX391168 B MX 391168B
Authority
MX
Mexico
Prior art keywords
sup
fatty acid
acid derivatives
lower alkyl
disorder
Prior art date
Application number
MX2019015730A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Ramsden
Gregory Keyes
Original Assignee
The Us Secretary Department Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Us Secretary Department Of Health & Human Services filed Critical The Us Secretary Department Of Health & Human Services
Publication of MX391168B publication Critical patent/MX391168B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C07C33/025—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond
    • C07C33/03—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond in beta-position, e.g. allyl alcohol, methallyl alcohol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019015730A 2017-07-07 2018-07-06 Derivados de acido graso y su uso. MX391168B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762529846P 2017-07-07 2017-07-07
PCT/US2018/041086 WO2019010414A1 (en) 2017-07-07 2018-07-06 FATTY ACID DERIVATIVES AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX391168B true MX391168B (es) 2025-03-21

Family

ID=63036390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015730A MX391168B (es) 2017-07-07 2018-07-06 Derivados de acido graso y su uso.

Country Status (9)

Country Link
US (2) US11555021B2 (enExample)
EP (1) EP3649115B1 (enExample)
JP (1) JP7234151B2 (enExample)
KR (1) KR102725883B1 (enExample)
CN (1) CN110869354A (enExample)
AU (1) AU2018297192B2 (enExample)
CA (1) CA3064132C (enExample)
MX (1) MX391168B (enExample)
WO (1) WO2019010414A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN113121475B (zh) * 2021-03-30 2022-12-02 香港科技大学深圳研究院 不饱和脂肪酸类化合物及其制备方法和应用
CN113620923B (zh) * 2021-07-16 2023-03-14 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN115073295B (zh) * 2022-07-21 2023-12-26 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用
WO2024237316A1 (ja) * 2023-05-16 2024-11-21 国立大学法人東京大学 エポキシ化不飽和脂肪酸の皮膚線維化改善作用
EP4613730A1 (en) * 2024-03-05 2025-09-10 Centre National de la Recherche Scientifique Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055613A (en) * 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
ATE168372T1 (de) * 1993-03-29 1998-08-15 Hsc Res Dev Lp Hepoxilin analoga verwendbar als entzündungshemmende mittel
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
BR0012447A (pt) * 1999-07-15 2002-04-02 Lilly Co Eli Análogos de pseudomicina de cadeia lateral de n-acila
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
DE102004037118A1 (de) 2004-07-30 2006-03-23 Degussa Ag Titandioxid enthaltende Dispersion
WO2006106438A2 (en) 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
JP5552121B2 (ja) * 2008-09-04 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
WO2013157926A1 (en) 2012-04-19 2013-10-24 Nyken Holding B.V. Geranyl geranyl acetone analogs and uses thereof
JP6160375B2 (ja) 2013-09-06 2017-07-12 ブラザー工業株式会社 画像記録装置

Also Published As

Publication number Publication date
EP3649115B1 (en) 2024-09-04
KR102725883B1 (ko) 2024-11-01
EP3649115A1 (en) 2020-05-13
AU2018297192B2 (en) 2022-02-17
US20220274940A1 (en) 2022-09-01
JP7234151B2 (ja) 2023-03-07
AU2018297192A1 (en) 2019-12-19
US20210139440A1 (en) 2021-05-13
CN110869354A (zh) 2020-03-06
WO2019010414A1 (en) 2019-01-10
CA3064132C (en) 2024-06-04
US12479812B2 (en) 2025-11-25
JP2020526505A (ja) 2020-08-31
KR20200027545A (ko) 2020-03-12
CA3064132A1 (en) 2019-01-10
EP3649115C0 (en) 2024-09-04
US11555021B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
ZA202006137B (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
CR20210071A (es) Derivados de pirazina fusionados como inhibidores de a2a/a2b
MX2020007027A (es) Aditivo de estabilizacion de molienda para molinos de rodillos verticales.
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX380928B (es) Inhibidores de kras g12c.
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2020003341A (es) Compuestos de imidazo-piridina como inhibidores de pad.
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EP4620528A3 (en) Bipyrazole derivatives as jak inhibitors
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
BR112015028174A2 (pt) composto, composição farmacêutica, uso de uma composição farmacêutica, e, métodos para modulação de atividade de receptores de andrógeno e para aumentar a biodisponibilidade de um modulador de receptor de andrógeno
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MX392664B (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc)
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
WO2015100092A3 (en) 7-beta analogs of orvinols
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
MX368214B (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
ZA202002762B (en) Benzimidazole derivatives and their uses
NZ620040A (en) Formulations of deoxycholic acid and salts thereof